News | 26 January 2022
Astec LifeSciences Q3FY22 PAT at Rs 24.74 cr.
Astec LifeSciences has reported its financial performance for the quarter ended December 31, 2021
Astec LifeSciences has reported its financial performance for the quarter ended December 31, 2021
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
The company has been manufacturing masks since the Covid-19 outbreak in 2020
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose
Avra Labs is a Hyderabad based contract manufacturing and research services (CRAMs) and specialty active pharmaceutical ingredients (API) manufacturer with four facilities across the states of Telangana and Andhra Pradesh
The country is sixth among the most affected countries by active cases
Previously, the use of the drug was limited to patients requiring hospitalization
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
An article by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center, has been published in medRxiv
Biocon has reported consolidated financial results for the period ended December 31, 2021
However, these won’t be available at the nearest chemist store soon
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
They will commercialize molnupiravir in the international markets
CliniSys has the proven ability to deliver 100s of millions of medical results a month to enable pandemic-scale population disease surveillance across the globe
This is the company’s first partnership arrangement in China
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
The acquisition would enable addition of established brands with high recall amongst healthcare professionals, especially in the vitamins, minerals and supplements category
Subscribe To Our Newsletter & Stay Updated
